NAVITOR™ TAVI SYSTEM

SMART SEALING. EXCEPTIONAL STABILITY. UNCOMPROMISED ACCESS.

Navitor™ TAVI system offers intelligent design advantages, including smart PVL-sealing NaviSeal™ Cuff, stable and accurate placement, exceptional single-digit gradients,[1] and uncompromised small vessel access and coronary access to consistently achieve excellent outcomes across a spectrum of routine to challenging anatomies.

1. Abbott data on file CL1014440.

Abbott

NAVITOR™ VALVE

INTELLIGENT DESIGN.

- Smart PVL-sealing NaviSeal™ Cuff
- Exceptional single-digit gradients[1]
- Uncompromised coronary access

LEARN MORE

FLEXNAV™ DELIVERY SYSTEM



STABILITY AND ACCURACY.

- Low profile 5.0 mm minimum vessel diameter for uncompromised small vessel access
- Enhanced flexibility for excellent deliverability
- Stable deployment and accurate valve placement

LEARN MORE

EXCELLENT OUTCOMES.

Clinical results demonstrate excellent outcomes across a spectrum of routine to challenging anatomies.

30-DAY[1]

0%	0%	0.8%	0.8%	7.4 mmHg
SEVERE TO MODERATE PVL	ALL CAUSE MORTALITY	DISABLING STROKE	MAJOR VASCULAR COMPLICATIONS	MEAN GRADIENT

1. Abbott data on file CL1014440.



NAVITOR™ VALVE

INTELLIGENT DESIGN.

Advancing the forefront of innovative design, the Navitor™ valve brings together smart PVL-sealing technology, exceptional single-digit gradients,[1] and uncompromised coronary access to achieve excellent clinical outcomes.

1. Abbott data on file CL1014440.

SMART SEALING. REMARKABLE PERFORMANCE.

NaviSeal™ Cuff actively synchronizes to the cardiac cycle, seals, and mitigates PVL[1] by expanding to fill calcification-related gaps between the annulus and the valve.

SMART SEALING MITIGATES PVL

30-DAY ECHO CORE LAB DATA[1]

80%	20%	0%	0%
NONE/TRACE	MILD	MODERATE	SEVERE

SEE THE EVIDENCE
Outperforming TAVI Systems

1. Abbott data on file CL1014440.

NAVITOR™ TAVI SYSTEM

SMART SEALING.

PVL 30-DAY ECHO CORE LAB DATA	NAVITOR™[1] N=118	EVOLUT‡ PRO[2] N=58	ACURATE NEO2‡[3] N=100	SAPIEN‡ 3[4] N=113*
None/Trace	**79.7%**	72.4%	35.0%	74.3%
Mild	**20.3%**	27.6%	62.0%	22.1%
Moderate	**0.0%**	0.0%	3.0%	3.5%
Severe	**0.0%**	0.0%	0.0%	0.0%

PVL IMPACT.

Moderate or greater PVL increases 1-year mortality and rehospitalization

2.4x-2.7x

following TAVI[5]

Based on number of subjects with data evaluable by the echo core lab.

NOTE: Data not from head-to-head studies. Data differences depicted between these trials may not be directly comparable, statistically significant, or clinically meaningful due to differences in trial protocols, endpoints, and/or patient populations. Data provided for informational purposes only.

NOTE: Referenced data reflect results from prospective, multicenter clinical studies with contemporary valves in high and extreme risk surgical patients conducted to support CE Mark approval.

* Includes data on subjects implanted via transapical and transaortic access.

1. Abbott data on file CL1014440.
2. Forrest JK, et al. Outcomes with the Evolut PRO repositionable self-expanding transcatheter aortic valve with pericardial wrap. J Am Coll Cardiol Intv. 2018;11:160-168.
3. Möllmann H. Transcather aortic valve implantation for severe aortic stenosis with the Acurate neo2 valve system: 30-day safety and performance outcomes. Abstract presented at: PCR London Valves; September 10, 2018; London, UK.
4. Webb J, et al. Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll Cardiol. 2014;64:2235-43.
5. Pibarot P, et al. Assessment of paravalvular regurgitation following TAVR: a proposal of unifying grading scheme. JACC Cardiovasc Imaging. 2015;8(3):340-360. doi: 10.1016/j.jcmg.2015.01.008. PMID: 25772838.

EXCEPTIONAL HEMODYNAMICS.

LARGE EFFECTIVE ORIFICE AREAS.[1] SINGLE-DIGIT GRADIENTS.[1]

30-DAY ECHO CORE LAB DATA[1]

2.0 cm^2
EOA

7.4 mmHg
MEAN GRADIENT



SEE THE EVIDENCE
Outperforming TAVI Systems

HEMODYNAMIC IMPACT.

Non-tapered stent and large EOAs resulting in single-digit gradients are associated with improved cardiac function, long-term durability, and minimal prosthesis-patient mismatch.[1]

1. Abbott data on file CL1014440.

NAVITOR™ TAVI SYSTEM

EXCEPTIONAL HEMODYNAMICS.

30-DAY ECHO CORE LAB DATA	NAVITOR™[1]	EVOLUT‡ PRO[2]	ACURATE NEO2‡[3]	SAPIEN‡ 3[4]
Mean Gradient (mmHg)	**7.4 (N=118)**	6.4 (N=55)	7.9 (N=104)	10.6 (N=119*)
EOA (cm^2)	**2.0 (N=101)**	2.0 (N=47)	1.7 (N=99)	1.5 (N=97*)

Based on number of subjects with data evaluable by the echo core lab.

NOTE: Data not from head-to-head studies. Data differences depicted between these trials may not be directly comparable, statistically significant, or clinically meaningful due to differences in trial protocols, endpoints, and/or patient populations. Data provided for informational purposes only.

NOTE: Referenced data reflect results from prospective, multicenter clinical studies with contemporary valves in high and extreme risk surgical patients conducted to support CE Mark approval.

* Includes data on subjects implanted via transapical and transaortic access.

1. Abbott data on file CL1014440.
2. Forrest JK, et al. Early outcomes with the Evolut PRO repositionable self-expanding transcatheter aortic valve with pericardial wrap. J Am Coll Cardiol Intv. 2018;11:160-168.
3. Möllmann H. Transcather aortic valve implantation for severe aortic stenosis with the Acurate neo2 valve system: 30-day safety and performance outcomes. Abstract presented at: PCR London Valves; September 10, 2018; London, UK.
4. Webb J, et al. Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll Cardiol. 2014;64:2235-43.

EXCEPTIONAL HEMODYNAMICS.

DESIGNED FOR IMMEDIATE FUNCTIONALITY AND DURABILITY.



CONTINUOUS STABILITY. NO RAPID PACING.

The only self-expanding valve with intra-annular leaflets that immediately function and a non-tapered stent, providing hemodynamic stability for a calm and controlled deployment.

DESIGNED FOR DURABILITY.

Exclusive Linx™ anticalcification (AC) technology resists calcification in four distinct ways to improve long-term valve performance.[1-4]

SEE THE EVIDENCE
Outperforming TAVI Systems

1. Frater RWM, et al. Advances in anticalcific and antidegenerative treatment of heart valve bioprostheses. Silent Partners Inc. 1997;8:105-13.
2. Kelly SJ, et al. Biocompatibility and calcification of bioprosthetic heart valves. Society for biomaterials. Sixth World Biomaterials Congress Transaction. 2000;13534.
3. Vyavahare N, et al. Prevention of bioprosthetic heart valve calcification by ethanol preincubation: efficacy and mechanisms. Circulation. 1997;95(2):479-88.
4. Vyavahare N, et al. Prevention of calcification of glutaraldehyde-crosslinked porcine aortic cusps by ethanol preincubation: mechanistic studies of protein structure and water-biomaterial relationships. J Biomed Mater Res. 1998;40(4):577-85.

NAVITOR™ TAVI SYSTEM

DESIGNED FOR DURABILITY.

	ABBOTT LINX™ AC*[1-4]	MEDTRONIC AOA‡*[5]	BOSTON SCIENTIFIC BIOFIX‡*	EDWARDS THERMAFIX‡*[6]
PRODUCTS	**NAVITOR™**	**EVOLUT‡ PRO**	**ACURATE NEO2‡**	**SAPIEN‡ 3**
Reduces free aldehydes[1,2]	✓	✓	Not Publicly Available	✓
Extracts lipids[3]	✓		Not Publicly Available	✓
Minimizes uptake of cholesterol[4]	✓		Not Publicly Available	
Stabilizes leaflet collagen[4]	✓		Not Publicly Available	

* There is no clinical data currently available that evaluates the long-term impact of anticalcification tissue treatment in humans.

1. Frater RWM, et al. Advances in anticalcific and antidegenerative treatment of heart valve bioprostheses. Silent Partners Inc. 1997;8:105-13.
2. Kelly SJ, et al. Biocompatibility and calcification of bioprosthetic heart valves. Society for biomaterials. Sixth World Biomaterials Congress Transaction. 2000;13534.
3. Vyavahare N, et al. Prevention of bioprosthetic heart valve calcification by ethanol preincubation: efficacy and mechanisms. Circulation. 1997;95(2):479-88.
4. Vyavahare N, et al. Prevention of calcification of glutaraldehyde-crosslinked porcine aortic cusps by ethanol preincubation: mechanistic studies of protein structure and water-biomaterial relationships. J Biomed Mater Res. 1998;40(4):577-85.
5. Gross J. Calcification of bioprosthetic heart valves and its assessment. J Thorac Cardiovasc Surg. 2003;125:6-8.
6. Edwards website, http://www.webcitation.org/667ClPuMH. This WebCitation captured Edwards' site on 12MAR2012.

Information contained herein for **DISTRIBUTION outside of the U.S. ONLY**.
Always check the regulatory status for the device in your region.



UNCOMPROMISED CORONARY ACCESS.

Large-cell geometry and intra-annular valve design preserve coronary access for future intervention.

SEE THE EVIDENCE
Outperforming TAVI Systems

NAVITOR™ TAVI SYSTEM

UNCOMPROMISED CORONARY ACCESS.

VALVE SIZE	NAVITOR™*1	EVOLUT‡ PRO*1
23 mm	14.6 F	12.1 F
25 mm	16.3 F	n/a
26 mm	n/a	11.8 F
27 mm	18.7 F	n/a
29 mm	21.0 F	11.9 F

29 mm NAVITOR™ VALVE*1



36 CELLS TOTAL

9 CELLS IN THE ANNULUS SECTION OF THE STENT

29 mm EVOLUT‡ PRO VALVE*1

135 CELLS TOTAL

15 CELLS IN THE ANNULUS SECTION OF THE STENT

* Based on Abbott coronary access testing.

1. Abbott data on file 90664679.



FLEXNAV™ DELIVERY SYSTEM

STABILITY AND ACCURACY.

- Low profile and highly flexible catheter enables excellent deliverability, even in patients with small access vessels and tortuous anatomies
- Controlled deployment provides stable and accurate valve placement
- Recapturable,** repositionable,** and retrievable** design

14 F* DELIVERY SYSTEM WITH

5.0 mm

minimum vessel diameter

SEE THE EVIDENCE
Outperforming TAVI Systems



* 14 F equivalent integrated sheath diameter.

** Until fully deployed.

NAVITOR™ TAVI SYSTEM

UNCOMPROMISED SMALL VESSEL ACCESS.

	NAVITOR™ WITH FLEXNAV™[1]	EVOLUT‡ PRO WITH ENVEO‡ PRO[2]	ACURATE NEO2‡ WITH iSLEEVE‡[3,4]	SAPIEN‡ 3 WITH eSHEATH‡[5,6]
Delivery System Profile (Outer Diameter)	**6.0 mm** **6.3 mm**	6.7 mm	6.0 mm	7.6 mm 8.2 mm
Minimum Vessel Diameter	**5.0 mm** **5.5 mm**	5.5 mm	5.5 mm	5.5 mm 6.0 mm

1. Navitor™ TAVI System IFU.
2. Medtronic CoreValve Evolut‡ PRO IFU.
3. Boston Scientific Acurate neo2‡ IFU.
4. Boston Scientific iSleeve‡ IFU.
5. Edwards Sapien 3‡ IFU.
6. Koehler Sapien 3‡ eSheath OD BMRI 2015.

Information contained herein for **DISTRIBUTION outside of the U.S. ONLY**.
Always check the regulatory status for the device in your region.

NAVITOR™ TAVI SYSTEM

EXCELLENT OUTCOMES.

30-DAY[1]

0%	0%	0.8%	0.8%	7.4 mmHg
SEVERE TO MODERATE PVL	ALL CAUSE MORTALITY	DISABLING STROKE	MAJOR VASCULAR COMPLICATIONS	MEAN GRADIENT

SEE THE EVIDENCE
Outperforming TAVI Systems

1. Abbott data on file CL1014440.

NAVITOR™ TAVI SYSTEM

EXCELLENT OUTCOMES.

30-DAY	NAVITOR™[1] N=120	EVOLUT‡ PRO[2] N=60	ACURATE NEO2‡[3] N=120	SAPIEN‡ 3[4] N=96*
All-Cause Mortality	**0.0%**	1.7%	3.3%	2.1%
Disabling Stroke	**0.8%**	1.7%	1.7%	0.0%
Life-Threatening Bleeding	**2.5%**	11.7%	5.0%	3.1%
Acute Kidney Injury Stage 2/3	**1.7%**	1.7%	0.8%	1.0%
Major Vascular Complications	**0.8%††**	10.0%	3.3%	4.2%
New Permanent Pacemaker Implantation	**15.0%**	11.8%	16.1%	14.5%

NOTE: Data not from head-to-head studies. Data differences depicted between these trials may not be directly comparable, statistically significant, or clinically meaningful due to differences in trial protocols, endpoints, and/or patient populations. Data provided for informational purposes only.

NOTE: Referenced data reflect results from prospective, multicenter clinical studies with contemporary valves in high and extreme risk surgical patients conducted to support CE Mark approval.

* Transfemoral access cohort.
†† 0% TAVI delivery system access site-related, 0.8% non-TAVI delivery system access site-related, and 0% non-access site-related.

1. Abbott data on file CL1014440.
2. Forrest JK, et al. Early outcomes with the Evolut PRO repositionable self-expanding transcatheter aortic valve with pericardial wrap. J Am Coll Cardiol Intv. 2018;11:160-168.
3. Möllmann H. Transcather aortic valve implantation for severe aortic stenosis with the Acurate neo2 valve system: 30-day safety and performance outcomes. Abstract presented at: PCR London Valves; September 10, 2018; London, UK.
4. Webb J, et al. Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll Cardiol. 2014;64:2235-43.

Information contained herein for **DISTRIBUTION outside of the U.S. ONLY**.
Always check the regulatory status for the device in your region.

SMART SEALING. EXCEPTIONAL STABILITY. UNCOMPROMISED ACCESS.

EXPERIENCE EXCELLENT OUTCOMES WITH THE NAVITOR™ TAVI SYSTEM.

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Information contained herein for **DISTRIBUTION outside of the U.S. ONLY**. Always check the regulatory status for the device in your region.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Photo(s) on file at Abbott.

Abbott
3200 Lakeside Dr., Santa Clara, CA 95054 USA

www.structuralheart.abbott

Abbott